Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extended peginterferon alfa-2b plus ribavirin in HIV/HCV coinfected slow early virologic responders
2005-004699-19Phase 4Active
- Sponsor
- Vicente Soriano
- Start
- Jan 2006
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of peginterferon alfa-2b and ribavirin in hepatitis C virus infection and human immunodeficiency virus infection (HIV) (2 arms), sponsored by Vicente Soriano. Primary endpoint: Sustained virologic response for hepatitis C virus. Started Jan 2006; status: active.
02
Drugs
peginterferon alfa-2bribavirin
03
Conditions
hepatitis C virus infectionhuman immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2005-004699-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-004699-19.